Patrick Staropoli, MD
Ophthalmology · Bellaire, TXNPI 1780117929
Payments from drug & device makers
Across 134 payments — averaging $279.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$23K
- Ocular Therapeutix, Inc.$4K
- Genentech USA, Inc.$3K
- Eyepoint US, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Alcon$788
- plus $4K from 12 others
What the payments were for
- Consulting fees$28,22275%
- Travel & lodging$1,4904%
- Food & beverage$7,77121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 27 | $22,875 |
| Ocular Therapeutix, Inc. | 3 | $3,737 |
| Genentech USA, Inc. | 15 | $3,035 |
| Eyepoint US, Inc. | 2 | $1,949 |
| Regeneron Healthcare Solutions, Inc. | 27 | $1,491 |
| Alcon | 6 | $788 |
| AbbVie(2 entities) | 9 | $739 |
| Regeneron | 6 | $531 |
| Astellas Pharma US Inc | 17 | $501 |
| Mallinckrodt Enterprises LLC | 4 | $475 |
| Alimera Sciences, Inc. | 7 | $457 |
| Harrow Eye, LLC | 1 | $162 |
| Genentech, Inc. | 1 | $151 |
| Dutch Ophthalmic, USA | 2 | $137 |
| Biotissue Holdings Inc. | 2 | $131 |
| ANI Pharmaceuticals, Inc. | 1 | $130 |
| Dompe US, Inc. | 1 | $125 |
| Biogen | 3 | $70 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,483 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 86 | $4,436 |
| Bromfenac Sodium | 17 | $3,926 |
| ProlensaBromfenac Sodium | 11 | $3,835 |
| MoxifloxacinMoxifloxacin Hcl | 41 | $1,035 |
| Atropine Sulfate | 27 | $834 |
| Ketorolac Tromethamine | 32 | $593 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $329 |
| Latanoprost | 22 | $222 |
| Brimonidine Tartrate | 18 | $116 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $76 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Bellaire
- Charles WykoffBellaire$73.4M
- Hasenin Al-KhersanBellaire$1.9M
- Effie RahmanBellaire$555K
- Otis WaltonBellaire$493K
- Kelly LarkinBellaire$486K
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.